178 related articles for article (PubMed ID: 26622608)
1.
Wang D; Wu X
Oncol Lett; 2015 Aug; 10(2):975-981. PubMed ID: 26622608
[TBL] [Abstract][Full Text] [Related]
2. Metformin enhances anti-cancer effects of cisplatin in meningioma through AMPK-mTOR signaling pathways.
Guo L; Cui J; Wang H; Medina R; Zhang S; Zhang X; Zhuang Z; Lin Y
Mol Ther Oncolytics; 2021 Mar; 20():119-131. PubMed ID: 33575476
[TBL] [Abstract][Full Text] [Related]
3. Metformin in combination with 5-fluorouracil suppresses tumor growth by inhibiting the Warburg effect in human oral squamous cell carcinoma.
Harada K; Ferdous T; Harada T; Ueyama Y
Int J Oncol; 2016 Jul; 49(1):276-84. PubMed ID: 27210058
[TBL] [Abstract][Full Text] [Related]
4. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
5. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways.
Wang Y; Xu W; Yan Z; Zhao W; Mi J; Li J; Yan H
J Exp Clin Cancer Res; 2018 Mar; 37(1):63. PubMed ID: 29554968
[TBL] [Abstract][Full Text] [Related]
6. Targeting renal cell carcinoma with gambogic acid in combination with sunitinib in vitro and in vivo.
Jiang XL; Zhang Y; Luo CL; Wu XH
Asian Pac J Cancer Prev; 2012; 13(12):6463-8. PubMed ID: 23464475
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
8. Targeting colorectal cancer cell metabolism through development of cisplatin and metformin nano-cubosomes.
Saber MM; Al-Mahallawi AM; Nassar NN; Stork B; Shouman SA
BMC Cancer; 2018 Aug; 18(1):822. PubMed ID: 30111296
[TBL] [Abstract][Full Text] [Related]
9. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
10. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
11. β-elemene enhances cisplatin-induced apoptosis in bladder cancer cells through the ROS-AMPK signaling pathway.
Gan D; He W; Yin H; Gou X
Oncol Lett; 2020 Jan; 19(1):291-300. PubMed ID: 31897141
[TBL] [Abstract][Full Text] [Related]
12. Metformin Enhances Nomegestrol Acetate Suppressing Growth of Endometrial Cancer Cells and May Correlate to Downregulating mTOR Activity In Vitro and In Vivo.
Cao C; Zhou JY; Xie SW; Guo XJ; Li GT; Gong YJ; Yang WJ; Li Z; Zhong RH; Shao HH; Zhu Y
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284427
[TBL] [Abstract][Full Text] [Related]
13. Metformin enhances cisplatin induced inhibition of cholangiocarcinoma cells via AMPK-mTOR pathway.
Wandee J; Prawan A; Senggunprai L; Kongpetch S; Tusskorn O; Kukongviriyapan V
Life Sci; 2018 Aug; 207():172-183. PubMed ID: 29847773
[TBL] [Abstract][Full Text] [Related]
14. Metformin inhibits the proliferation of canine mammary gland tumor cells through the AMPK/AKT/mTOR signaling pathway
Fan Y; Ren X; Wang Y; Xu E; Wang S; Ge R; Liu Y
Oncol Lett; 2021 Dec; 22(6):852. PubMed ID: 34733370
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
[TBL] [Abstract][Full Text] [Related]
16. Targeting AMPK, mTOR and β-Catenin by Combined Metformin and Aspirin Therapy in HCC: An Appraisal in Egyptian HCC Patients.
Abdelmonsif DA; Sultan AS; El-Hadidy WF; Abdallah DM
Mol Diagn Ther; 2018 Feb; 22(1):115-127. PubMed ID: 29094287
[TBL] [Abstract][Full Text] [Related]
17. Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft.
Liu J; Li M; Song B; Jia C; Zhang L; Bai X; Hu W
Urol Oncol; 2013 Feb; 31(2):264-70. PubMed ID: 21676631
[TBL] [Abstract][Full Text] [Related]
18. Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase.
Guo Q; Liu Z; Jiang L; Liu M; Ma J; Yang C; Han L; Nan K; Liang X
Mol Med Rep; 2016 Mar; 13(3):2590-6. PubMed ID: 26847819
[TBL] [Abstract][Full Text] [Related]
19. Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt.
Janjetovic K; Vucicevic L; Misirkic M; Vilimanovich U; Tovilovic G; Zogovic N; Nikolic Z; Jovanovic S; Bumbasirevic V; Trajkovic V; Harhaji-Trajkovic L
Eur J Pharmacol; 2011 Jan; 651(1-3):41-50. PubMed ID: 21114978
[TBL] [Abstract][Full Text] [Related]
20. Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP.
Zhang T; Wang X; He D; Jin X; Guo P
Anticancer Drugs; 2014 Sep; 25(8):887-97. PubMed ID: 24714080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
